The Fall from Mythological Status: Why Did Pianzihuang’s “Price-Hiking Miracle” Fail?
Hello, everyone. I’m your financial analyst.
Today, we’re going to talk about a company that was once revered as the “Moutai of medicines” – Pianzihuang.
If you follow the stock market or high-end consumer goods, you’ve probably heard of it. Over the past few years, it was like a financial product; people bought it not just for its medicinal properties but also for its value preservation and as a gift. Its stock price once soared above 480 yuan, with a price-earnings ratio of 150 times, making it seem like owning it would guarantee continuous profits.
But reality is harsh. In 2025, Pianzihuang delivered its worst performance since going public over two decades: both its revenue and net profit declined. Its stock price has fallen by more than 70% from its peak. The myth of its increasing value and scarcity is starting to crumble.
What exactly happened? Why would a monopolistic company with a “state-secret formula” end up in such a predicament? Today, we’ll break down this situation in simple terms.
---
I. Core Summary: From “Hard Currency” to “Ordinary Medicine”
In short, Pianzihuang’s past high growth wasn’t due to its medicinal effectiveness but rather to its scarcity and financial attributes. By exploiting its state-secret formula and the limited supply of natural musk, it created an artificial scarcity. It continuously raised prices, attracting non-medical demand (for gifts, collection, speculation). People saw it as a valuable asset, similar to gold, and started hoarding it.
But now the financial bubble has burst:
1. Decline in non-medical demand: People no longer see it as valuable, so fewer people are buying it for gifts or for speculation.
2. Price hikes no longer work: In the past, price increases led to purchases; now, they just lead to price drops (dealers are selling at lower prices than they bought them for).
3. Failing to develop a second growth strategy: The company tried to diversify into cosmetics, Angong Niuhuang Pills, and innovative drugs, but after ten years, none of these areas have become a major source of revenue.
The result is that although sales have increased, they’re mostly from cheaper products; the high-priced core products aren’t selling, leading to a significant drop in total revenue and profits. Pianzihuang is being forced to return from a “luxury/investment product” to its basic role as a medicine.
---
II. In-Depth Analysis: Understanding Pianzihuang’s Dilemma from Five Perspectives
1. Performance Truth: Increased Sales, But Less Money? This is a “Structural Collapse”
Many people might think, “Sales increased by 25.81% – how can there still be a loss?” But there’s a big misunderstanding. We need to look at what’s being sold:
- Previously: High-priced core pills (600-760 yuan per piece) were the main source of profit, with a gross margin of over 60%.
- Now: Sales of these high-priced pills have dropped by 21%, while sales of cheaper products have increased by 41%.
It’s like a shop that used to sell Hermes bags for 100,000 yuan; now no one buys those, so it starts selling 1,000-yuan tissues. Even though more tissues are sold, total revenue and profit have decreased significantly.
Data Proof:
- In 2025, revenue from liver disease medications (mainly Pianzihuang pills) fell by 19.63%.
- Revenue from the pharmaceutical manufacturing sector (the main profit source) fell by 17.87%.
- Net profit fell by 27.49%.
Conclusion: This isn’t just about poor sales; it’s a collapse in high-end demand. The core products that supported its high valuation have lost their key consumer groups (speculators and the high-end gift market).
2. The Erosion of its Competitive Edge: Why Isn’t the “Secret Formula” Invincible?
Pianzihuang’s biggest strengths were its state-secret formula and the limited supply of natural musk. But this advantage has become ineffective due to price factors:
- Scarcity doesn’t equal essential demand: People bought it because of scarcity and expected price increases. This was an investment strategy.
- Price threshold exceeded: In 2023, Pianzihuang raised the retail price from 590 yuan to 760 yuan, which broke consumers’ expectations.
- Previously: 590 yuan seemed expensive, but with a potential 10-yuan profit, it was worth buying.
- Now: 760 yuan seems too expensive, and there’s a fear of losing money if the price drops.
Psychological Shift: The expectation has changed from “buy early for a profit” to “buy and lose value immediately.” This has led to dealers avoiding stockpiling, and consumers are reluctant to pay high prices.
Result: Dealers are selling products at lower prices, and sales have slowed. The monopoly remains, but the market’s willingness to pay has diminished.
3. Transformation Dilemma: Why Have Ten Years of “Second Growth Strategies” Failed?
With limited production capacity (due to musk quotas), Pianzihuang started looking for alternative growth areas. Since 2014, it’s been trying to diversify, but with little success:
- Cosmetics: Expected to generate billions in revenue, but in 2025, revenue from this segment only reached 567 million yuan, a 43% drop.
- Reasons: Intense competition from brands like L’Oréal and Yves Saint Laurent, and the fading popularity of “Chinese ingredients.”
- Angong Niuhuang Pills: Aimed to be a high-end gift medicine, but revenue fell by 59%.
- Reasons:
- No exclusive rights; many companies can produce it.
- High costs due to rising natural牛黄 prices, resulting in low margins.
- Strong competition from established brands like Tongrentang.
- Innovative Drugs: Expected to be a future growth driver, but with less than 3% of revenue invested in research (compared to 10%+ in innovative companies).
- Reasons: Insufficient funding and slow progress; the fastest drugs are still in clinical trials.
Conclusion: Pianzihuang’s diversification efforts have been ineffective. It’s either competing in a crowded market (cosmetics) or trying to compete with giants (Angong Niuhuang Pills) or investing in unprofitable fields (innovative drugs).
4. Costs and Profit: Rising Prices of Natural Ingredients
Another issue is the high cost of natural ingredients:
- Musk: Limited supply, but the impact is limited due to a fixed quota system.
- Niuhuang: Prices are highly volatile. Pianzihuang bought large quantities at high prices, which now affects its margins.
- Good News: In the first half of 2026, margins improved slightly as cheaper niuhuang was used.
- Bad News: This only provides temporary relief and doesn’t solve the underlying revenue issue.
5. Valuation Shift: From “Financial Stock” to “Medicine Stock”
The market is honest:
- Previously (2021): Price-earnings ratio of 150 times, treated as a “financial stock/luxury product.”
- Now: The ratio has dropped significantly, as the market sees it as a “traditional medicine stock” with stable demand but limited growth and cost pressures.
Changes in Valuation Logic:
1. Less reliance on financial gains: No longer expected to counter inflation or attract speculative funds through price hikes.
2. Focus on fundamentals: Investors are looking at actual demand, inventory levels, and the effectiveness of diversification efforts.
3. Uncertainty: Frequent changes in leadership (3 CEOs since 2021) have raised doubts about strategic consistency.
Future Outlook:
- Short Term: Performance pressure remains; time is needed to reduce high inventory and rebuild dealer confidence.
- Medium Term: Margins may improve with lower niuhang prices, but revenue growth is weak.
- Long Term: Unless there’s a breakthrough in innovative drugs or a new growth strategy, Pianzihuang will experience slow growth. It’s still a good company with barriers and cash flow, but it’s no longer the “surefire investment” it once was.
---
III. Lessons for Everyone
1. Don’t Overestimate Scarcity and Price Hikes: Any product that’s priced beyond its value will collapse quickly if expectations change.
2. Be Cautious of Overreliance on One Product: Relying on one product for over 90% of profits is risky, especially in tough times.
3. Evaluate Diversification Efforts: Check if the company has unique advantages and sufficient R&D investment in new areas.
4. Monitor Channel Inventory and Price Trends: Terminal price drops indicate declining confidence, which can harm performance.
In Summary:
Pianzihuang isn’t “dead”; its strengths still exist, and it’s financially healthy. But its mythological status is over. It will become a good, albeit slower-growing traditional Chinese medicine company. For investors, the high valuation bubble has burst, and a new growth story needs to be established. Patience is key.